Cybersecurity

UFP Technologies Reports Cyberattack and Data Breach
Regulatory & Compliance UFP Technologies Reports Cyberattack and Data Breach

When a manufacturer responsible for critical medical device components experiences a total halt in its digital operations, the consequences ripple far beyond the walls of its corporate headquarters and into the healthcare facilities that rely on its timely deliveries. UFP Technologies, a prominent

J&J Heart Pump Flaw Linked to 22 Serious Injuries
Regulatory & Compliance J&J Heart Pump Flaw Linked to 22 Serious Injuries

In the high-stakes environment of cardiac care, where precision instruments can mean the difference between life and death, the reliability of medical technology is paramount. A significant safety concern has now emerged surrounding a critical device, as Johnson & Johnson's subsidiary, Abiomed,

Is Healthcare Ready for AI Cyber Threats?
Digital Health Is Healthcare Ready for AI Cyber Threats?

We're joined today by James Maitland, a leading expert in medical robotics and IoT applications, whose work focuses on integrating advanced technology safely and effectively into healthcare. With the explosion of generative AI, the healthcare sector faces a dual reality: unprecedented opportunity

FDA Refuses to Review Moderna's mRNA Flu Vaccine
Regulatory & Compliance FDA Refuses to Review Moderna's mRNA Flu Vaccine

A Regulatory Standoff with High Stakes In a move that sent shockwaves through the biotechnology sector, the U.S. Food and Drug Administration (FDA) has taken the extraordinary step of refusing to conduct a formal review of Moderna's biologics license application for its mRNA-based influenza

FDA Device Approvals Rise Despite Staffing Cuts
Regulatory & Compliance FDA Device Approvals Rise Despite Staffing Cuts

In a surprising display of resilience, the U.S. Food and Drug Administration’s Center for Devices and Radiological Health (CDRH) not only maintained its operational tempo but also increased its authorization of novel medical devices in 2025, a period marked by significant staff reductions under the

Is PBM Transparency the Key to Cheaper Drugs?
Regulatory & Compliance Is PBM Transparency the Key to Cheaper Drugs?

A Federal Reckoning: Targeting the Middlemen of Medicine The persistent and escalating cost of prescription drugs in the United States has ignited widespread public frustration and become a recurring battleground in political debate. A proposed rule from the Department of Labor (DOL) is now taking

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later